Discuss the strategic importance of indigenising bulk drug (API) manufacturing. What are the bottlenecks?

Q. Discuss the strategic importance of indigenising bulk drug (API) manufacturing. What are the bottlenecks? (15 marks, 250-350 words)

Bulk drugs — Key Starting Materials (KSMs), Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) — are the chemical core of every formulation. India, the "Pharmacy of the World", still imports a high share of these inputs, largely from a single source country, making indigenisation a question of health security, not merely industrial policy [1].

Strategic importance

• Supply-chain resilience: COVID-19 border closures exposed the risk of single-source dependence. The PLI scheme for KSMs/DIs/APIs (2020, ₹6,940 crore outlay) targets 41 identified bulk drugs with the highest import dependence [3], and has already enabled import avoidance worth ₹3,591 crore [4].
• Affordability and Right to Health: cheap domestic APIs are the input base for generics sold through Jan Aushadhi Kendras, which grew from 84 (2014) to 19,200+ (2026) and saved citizens over ₹40,000 crore [1].
• Economic depth: Bulk Drug Parks in Andhra Pradesh, Gujarat and Himachal Pradesh, with ₹1,000 crore central assistance each, provide subsidised power, water and effluent treatment to cluster API units [2]. PLI-Pharma has drawn ₹42,694 crore investment and 1.13 lakh+ jobs [1].
• Diplomatic leverage: secure API supply sustains India's vaccine and generic exports to 200+ countries [1].

Bottlenecks

• Cost disadvantage: competitors enjoy larger scale and subsidised utilities; Indian API costs remain structurally higher.
• Technology gap: limited capability in fermentation-based APIs, which are capital- and energy-intensive.
• Environmental burden: API manufacture is effluent-heavy; clearances and ETP costs delay projects — the very gap common infrastructure in parks seeks to close [2].
• Implementation lags: land acquisition and utility creation in parks progress slowly.
• Regulatory fragmentation: CDSCO regulates quality, NPPA caps prices under DPCO 2013, DoP runs schemes — with price ceilings compressing margins on low-value APIs.
• Thin R&D base, keeping India dependent on imported process technology.

Indigenisation is thus both a resilience shield and a growth engine. A calibrated path — sustaining PLI beyond its tenure, fast-tracking park infrastructure, incentivising green chemistry and fermentation R&D, and harmonising price control with viability — can convert India's formulation strength into genuine value-chain self-reliance, anchoring Atmanirbhar Bharat in SDG-3's promise of affordable health for all.

(~330 words)

Sources: 1. 12 Years of Transformative Growth in Pharmaceuticals Sector, PIB (17 June 2026) — Jan Aushadhi Kendra growth, ₹40,000 crore citizen savings, PLI-Pharma investment and employment, "Pharmacy of the World" 2. Bulk Drug Parks, PIB — three parks in AP/Gujarat/HP, ₹1,000 crore central assistance each, subsidised utilities and effluent treatment 3. Approvals under PLI Scheme for KSMs/DIs/APIs, PIB — ₹6,940 crore outlay, 41 identified bulk drugs, high import dependence 4. Measures to encourage domestic manufacturing in the Pharmaceutical Sector, PIB — import avoidance of ₹3,591 crore in APIs/KSMs/DIs